IIVS | Reconstructed Skin Micronucleus (RSMN)
624
page-template-default,page,page-id-624,page-child,parent-pageid-544,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-4.11.2.1,vc_responsive

Reconstructed Skin Micronucleus (RSMN)

Reconstructed Skin Micronucleus (RSMN) Using the EpiDermâ„¢ Reconstructed Human Epidermis Model

RSMN is used to evaluate the genotoxicity potential of the test article to the EpiDermâ„¢ Skin Model. Genotoxicity potential is determined by assessing whether the micronucleus frequency in tissues exposed to the test article showed a statistically significant increase relative to the tissues exposed to the solvent (negative) control.

Evaluate the genotoxic potential of new ingredients and chemicals at exposure-relevant doses

  • RSMN determines the skin genotoxicity/mutagenicity potential of a test substance by determining the relative increase in the induction of micronuclei in test substance- treated tissues compared to negative control-treated tissues
  • Reconstructed human epidermal tissues may more accurately model the complexity of skin absorption, human epidermal metabolism, and tissue-specific responses than traditional monolayer culture systems
  • Complex test formulations may be applied in a biologically-relevant fashion directly onto the stratum corneum
  • Protocols allow for 48 and 72 hour exposures on the metabolically active tissues with no exogenous source of metabolic activation (S9)
  • Scientific Committee on Consumer Safety (SCCS) of European Commission acknowledges potential uses of RSMN as a 2nd tier genotoxicity testing

Assays of Interest